FDA Inspection 1200624 — Roswell Park Cancer Institute Corporation. Div. Of Pathology
The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. Of Pathology on Mar 13, 2023 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 13, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Buffalo, NY (United States)